Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Short Interest Update

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) was the target of a large drop in short interest in November. As of November 15th, there was short interest totalling 4,590,000 shares, a drop of 18.9% from the October 31st total of 5,660,000 shares. Based on an average daily volume of 2,490,000 shares, the short-interest ratio is presently 1.8 days.

Marinus Pharmaceuticals Price Performance

Shares of Marinus Pharmaceuticals stock opened at $0.33 on Monday. Marinus Pharmaceuticals has a 1-year low of $0.26 and a 1-year high of $11.26. The company’s fifty day simple moving average is $0.98 and its 200-day simple moving average is $1.23. The stock has a market capitalization of $17.94 million, a PE ratio of -0.13 and a beta of 1.26.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. Oppenheimer raised Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price target on the stock in a report on Monday, September 23rd. Truist Financial cut shares of Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 24th. LADENBURG THALM/SH SH lowered shares of Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 14th. JMP Securities restated a “market perform” rating on shares of Marinus Pharmaceuticals in a research report on Thursday, October 24th. Finally, Royal Bank of Canada cut their target price on shares of Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating for the company in a research report on Friday, October 25th. Nine investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Marinus Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $4.79.

Hedge Funds Weigh In On Marinus Pharmaceuticals

A number of institutional investors have recently bought and sold shares of MRNS. Franklin Resources Inc. grew its holdings in Marinus Pharmaceuticals by 34.9% during the third quarter. Franklin Resources Inc. now owns 4,713,014 shares of the biopharmaceutical company’s stock valued at $8,483,000 after purchasing an additional 1,219,871 shares during the period. World Investment Advisors LLC purchased a new position in shares of Marinus Pharmaceuticals during the 3rd quarter valued at about $104,000. Jacobs Levy Equity Management Inc. grew its stake in shares of Marinus Pharmaceuticals by 39.5% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 414,269 shares of the biopharmaceutical company’s stock valued at $729,000 after acquiring an additional 117,255 shares during the period. Suvretta Capital Management LLC increased its holdings in Marinus Pharmaceuticals by 32.8% in the 3rd quarter. Suvretta Capital Management LLC now owns 5,073,913 shares of the biopharmaceutical company’s stock worth $8,930,000 after acquiring an additional 1,253,901 shares in the last quarter. Finally, GSA Capital Partners LLP raised its stake in Marinus Pharmaceuticals by 409.4% during the 3rd quarter. GSA Capital Partners LLP now owns 1,016,634 shares of the biopharmaceutical company’s stock worth $1,789,000 after acquiring an additional 817,050 shares during the period. 98.80% of the stock is owned by institutional investors.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.